Critical Survey: Caladrius Biosciences (CLBS) & BioRestorative Therapies (BRTX)

Caladrius Biosciences (NASDAQ:CLBS) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

6.9% of Caladrius Biosciences shares are held by institutional investors. 7.5% of Caladrius Biosciences shares are held by company insiders. Comparatively, 43.2% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Caladrius Biosciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Caladrius Biosciences and BioRestorative Therapies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Caladrius Biosciences $35.28 million 1.25 $22.97 million ($1.78) -2.54
BioRestorative Therapies $80,000.00 123.75 -$9.44 million N/A N/A

Caladrius Biosciences has higher revenue and earnings than BioRestorative Therapies.


This table compares Caladrius Biosciences and BioRestorative Therapies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences N/A -33.99% -27.21%
BioRestorative Therapies -9,030.91% N/A -712.11%

Analyst Ratings

This is a breakdown of current recommendations for Caladrius Biosciences and BioRestorative Therapies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 2 0 3.00
BioRestorative Therapies 0 0 0 0 N/A

Caladrius Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 142.83%. Given Caladrius Biosciences’ higher probable upside, analysts plainly believe Caladrius Biosciences is more favorable than BioRestorative Therapies.


Caladrius Biosciences beats BioRestorative Therapies on 7 of the 11 factors compared between the two stocks.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply